Welcome to LookChem.com Sign In|Join Free

CAS

  • or
Methyl 3-aMino-5-fluorobenzoate is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

884497-46-5 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 884497-46-5 Structure
  • Basic information

    1. Product Name: Methyl 3-aMino-5-fluorobenzoate
    2. Synonyms: Methyl 3-aMino-5-fluorobenzoate;Benzoic acid, 3-aMino-5-fluoro-, Methyl ester;3-Amino-5-fluorobenzoic acid methyl ester;3-amino-5-fluorobenzoate methyl
    3. CAS NO:884497-46-5
    4. Molecular Formula: C8H8FNO2
    5. Molecular Weight: 169.1530232
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 884497-46-5.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: 296.6±25.0 °C(Predicted)
    3. Flash Point: N/A
    4. Appearance: White to yellow/Solid
    5. Density: 1.264±0.06 g/cm3(Predicted)
    6. Refractive Index: N/A
    7. Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
    8. Solubility: N/A
    9. PKA: 2.44±0.10(Predicted)
    10. Water Solubility: Slightly soluble in water.
    11. CAS DataBase Reference: Methyl 3-aMino-5-fluorobenzoate(CAS DataBase Reference)
    12. NIST Chemistry Reference: Methyl 3-aMino-5-fluorobenzoate(884497-46-5)
    13. EPA Substance Registry System: Methyl 3-aMino-5-fluorobenzoate(884497-46-5)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 884497-46-5(Hazardous Substances Data)

884497-46-5 Usage

Uses

Methyl 3-amino-5-fluorobenzoate is an amino acid widely used in pharmaceuticals and foods.

Check Digit Verification of cas no

The CAS Registry Mumber 884497-46-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,4,4,9 and 7 respectively; the second part has 2 digits, 4 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 884497-46:
(8*8)+(7*8)+(6*4)+(5*4)+(4*9)+(3*7)+(2*4)+(1*6)=235
235 % 10 = 5
So 884497-46-5 is a valid CAS Registry Number.

884497-46-5 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Alfa Aesar

  • (H63038)  Methyl 3-amino-5-fluorobenzoate, 98%   

  • 884497-46-5

  • 250mg

  • 223.0CNY

  • Detail
  • Alfa Aesar

  • (H63038)  Methyl 3-amino-5-fluorobenzoate, 98%   

  • 884497-46-5

  • 1g

  • 671.0CNY

  • Detail
  • Alfa Aesar

  • (H63038)  Methyl 3-amino-5-fluorobenzoate, 98%   

  • 884497-46-5

  • 5g

  • 2685.0CNY

  • Detail

884497-46-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name methyl 3-amino-5-fluorobenzoate

1.2 Other means of identification

Product number -
Other names Methyl 5-Amino-3-fluorobenzoate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:884497-46-5 SDS

884497-46-5Relevant articles and documents

From off-to on-target: New BRAF-inhibitor-template-derived compounds selectively targeting mitogen activated protein kinase kinase 4 (MKK4)

Kl?vekorn, Philip,Pfaffenrot, Bent,Juchum, Michael,Selig, Roland,Albrecht, Wolfgang,Zender, Lars,Laufer, Stefan A.

supporting information, (2020/11/20)

The mitogen-activated protein kinase (MAP) kinase 4 (MKK4) was found to be a major regulator of liver regeneration and could be a valuable drug target addressing liver related diseases by restoring its intrinsic regenerative capacity. We report on the synthesis and optimization of novel MKK4 inhibitors following a target-hopping strategy from the FDA-approved BRAFV600E inhibitor PLX4032 (8). Applying an iterative multi-parameter optimization process we carved out essential structural features yielding in compounds with a low nanomolar affinity for MKK4 and excellent selectivity profiles against the main off-targets MKK7 and JNK1, which, upon relevant inhibition, would totally abrogate the pro-regenerative effect of MKK4 inhibition, as well as against the off-targets MAP4K5, ZAK and BRAF with selectivity factors ranging from 40 to 430 for our best-balanced compounds 70 and 73.

ΒETA-CATENIN AND B-CELL LYMPHOMA 9 (BCL9) INHIBITORS

-

Page/Page column 37; 39; 104, (2020/05/21)

Disclosed are inhibitors for the β-catenin/BCL9 interaction. The inhibitors are selective for β-catenin/BCL9 over β-catenin/cadherin interactions. Methods of using the disclosed compounds to treat cancer are also disclosed.

FUSED TETRA OR PENTA-CYCLIC PYRIDOPHTHALAZINONES AS PARP INHIBITORS

-

Paragraph 0227; 0231, (2017/12/01)

Provided are certain fused tetra or penta-cyclic compounds and salts thereof, compositions thereof, and methods of use thereof.

Aminoheteroaryl benzamides as kinase inhibitors

-

Page/Page column 280; 282, (2016/02/15)

The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

-

Page/Page column 68, (2015/02/19)

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

FUSED TETRA OR PENTA-CYCLIC PYRIDOPHTHALAZINONES AS PARP INHIBITORS

-

Paragraph 0276, (2015/02/18)

Provided are certain fused tetra or penta-cyclic compounds and salts thereof, compositions thereof, and methods of use thereof.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

-

Page/Page column, (2015/02/19)

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOUNDS AND USE THEREOF

-

Page/Page column 69, (2015/02/19)

Provided are therapeutically active compounds and the use in manufacture of medicaments for treating a cancer characterized by the presence of a mutant allele of IDH1.

FUSED TETRA OR PENTA-CYCLIC PYRIDOPHTHALAZINONES AS PARP INHIBITORS

-

Page/Page column 46; 47, (2013/07/19)

Provided are certain fused tetra or penta-cyclic compounds and salts thereof, compositions thereof, and methods of use thereof.

THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE

-

Page/Page column, (2013/07/31)

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 884497-46-5